FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234227889> ?p ?o ?g. }

• W4234227889 endingPage "1401" @default.
• W4234227889 startingPage "1395" @default.
• W4234227889 abstract "Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia.BackgroundExisting animal models of anemia inadequately reflect the hematocrit usually present in chronic renal failure (CRF) patients and do not permit long-term treatment studies. The transgenic mouse strain 134.3LC (Epo-TAgH) displays a severe chronic anemia resembling that observed clinically during CRF, while displaying an active, normal life span. This phenotype makes it a particularly interesting mouse model for testing erythropoietin (Epo)-based gene transfer strategies.MethodsEx vivo gene therapy was employed to administer mouse Epo to homozygous anemic Epo-TAgH mice. Encapsulated C2C12 myoblasts genetically engineered to secrete 163 IU mouse Epo/106 cells/day were subcutaneously transplanted on the dorsal flank of the mice. Efficacy of delivered Epo was monitored by weekly measurements of animal hematocrit.ResultsMost treated homozygous Epo-TAgH mice displayed only a transient rise in hematocrit before eventually decreasing to levels as low as 3%. Administering the immunosuppressor anti-CD4+ monoclonal antibody (mAb) to homozygous Epo-TAgH mice, beginning at the time of implantation, permitted a rise in hematocrit that remained stable at elevated levels in cases of continued immunosuppression.ConclusionsMice having the T antigen insertion in both Epo alleles appeared to develop an immune response to the natural mouse Epo delivered by encapsulated cells. By preventing this reaction using immunosuppression, we demonstrate that encapsulated myoblasts can deliver therapeutic doses of mouse Epo systemically and restore hemopoiesis in a genetic model of severe anemia. Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. Existing animal models of anemia inadequately reflect the hematocrit usually present in chronic renal failure (CRF) patients and do not permit long-term treatment studies. The transgenic mouse strain 134.3LC (Epo-TAgH) displays a severe chronic anemia resembling that observed clinically during CRF, while displaying an active, normal life span. This phenotype makes it a particularly interesting mouse model for testing erythropoietin (Epo)-based gene transfer strategies. Ex vivo gene therapy was employed to administer mouse Epo to homozygous anemic Epo-TAgH mice. Encapsulated C2C12 myoblasts genetically engineered to secrete 163 IU mouse Epo/106 cells/day were subcutaneously transplanted on the dorsal flank of the mice. Efficacy of delivered Epo was monitored by weekly measurements of animal hematocrit. Most treated homozygous Epo-TAgH mice displayed only a transient rise in hematocrit before eventually decreasing to levels as low as 3%. Administering the immunosuppressor anti-CD4+ monoclonal antibody (mAb) to homozygous Epo-TAgH mice, beginning at the time of implantation, permitted a rise in hematocrit that remained stable at elevated levels in cases of continued immunosuppression. Mice having the T antigen insertion in both Epo alleles appeared to develop an immune response to the natural mouse Epo delivered by encapsulated cells. By preventing this reaction using immunosuppression, we demonstrate that encapsulated myoblasts can deliver therapeutic doses of mouse Epo systemically and restore hemopoiesis in a genetic model of severe anemia." @default.
• W4234227889 created "2022-05-12" @default.
• W4234227889 creator A5000792302 @default.
• W4234227889 creator A5001356149 @default.
• W4234227889 creator A5036848232 @default.
• W4234227889 creator A5054985063 @default.
• W4234227889 creator A5059732570 @default.
• W4234227889 creator A5064727417 @default.
• W4234227889 creator A5087753311 @default.
• W4234227889 date "2002-10-01" @default.
• W4234227889 modified "2023-09-26" @default.
• W4234227889 title "Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia" @default.
• W4234227889 doi "https://doi.org/10.1046/j.1523-1755.2002.00574.x" @default.
• W4234227889 hasPublicationYear "2002" @default.
• W4234227889 type Work @default.
• W4234227889 citedByCount "1" @default.
• W4234227889 countsByYear W42342278892013 @default.
• W4234227889 crossrefType "journal-article" @default.
• W4234227889 hasAuthorship W4234227889A5000792302 @default.
• W4234227889 hasAuthorship W4234227889A5001356149 @default.
• W4234227889 hasAuthorship W4234227889A5036848232 @default.
• W4234227889 hasAuthorship W4234227889A5054985063 @default.
• W4234227889 hasAuthorship W4234227889A5059732570 @default.
• W4234227889 hasAuthorship W4234227889A5064727417 @default.
• W4234227889 hasAuthorship W4234227889A5087753311 @default.
• W4234227889 hasConcept C109159458 @default.
• W4234227889 hasConcept C126322002 @default.
• W4234227889 hasConcept C134018914 @default.
• W4234227889 hasConcept C203014093 @default.
• W4234227889 hasConcept C2778248108 @default.
• W4234227889 hasConcept C2778534260 @default.
• W4234227889 hasConcept C2780252810 @default.
• W4234227889 hasConcept C2780959883 @default.
• W4234227889 hasConcept C28328180 @default.
• W4234227889 hasConcept C71924100 @default.
• W4234227889 hasConcept C86803240 @default.
• W4234227889 hasConcept C95444343 @default.
• W4234227889 hasConceptScore W4234227889C109159458 @default.
• W4234227889 hasConceptScore W4234227889C126322002 @default.
• W4234227889 hasConceptScore W4234227889C134018914 @default.
• W4234227889 hasConceptScore W4234227889C203014093 @default.
• W4234227889 hasConceptScore W4234227889C2778248108 @default.
• W4234227889 hasConceptScore W4234227889C2778534260 @default.
• W4234227889 hasConceptScore W4234227889C2780252810 @default.
• W4234227889 hasConceptScore W4234227889C2780959883 @default.
• W4234227889 hasConceptScore W4234227889C28328180 @default.
• W4234227889 hasConceptScore W4234227889C71924100 @default.
• W4234227889 hasConceptScore W4234227889C86803240 @default.
• W4234227889 hasConceptScore W4234227889C95444343 @default.
• W4234227889 hasIssue "4" @default.
• W4234227889 hasLocation W42342278891 @default.
• W4234227889 hasOpenAccess W4234227889 @default.
• W4234227889 hasPrimaryLocation W42342278891 @default.
• W4234227889 hasRelatedWork W2098830437 @default.
• W4234227889 hasRelatedWork W2121791471 @default.
• W4234227889 hasRelatedWork W2137584496 @default.
• W4234227889 hasRelatedWork W2141708039 @default.
• W4234227889 hasRelatedWork W2148117411 @default.
• W4234227889 hasRelatedWork W2167902350 @default.
• W4234227889 hasRelatedWork W2366700700 @default.
• W4234227889 hasRelatedWork W2367281640 @default.
• W4234227889 hasRelatedWork W2805683016 @default.
• W4234227889 hasRelatedWork W2404988978 @default.
• W4234227889 hasVolume "62" @default.
• W4234227889 isParatext "false" @default.
• W4234227889 isRetracted "false" @default.
• W4234227889 workType "article" @default.